169 search results for: Pathophysiology
Clinical Manifestations Associated With Airway Remodeling in Asthma
Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.
Impact of Exacerbations in COPD
Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality
Role of Type 2 Cytokines in Asthma and COPD
Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.
Exacerbations Lead to Worsening Lung Function
Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.
Pediatric Asthma Trajectory and Clinical Remission
Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.
Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
Understanding Barriers to Advanced Systemic Therapy in AD
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis
Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
The Shared Path: Type 2 Inflammation As a Driver of Chronic Itch
Professor Matthias Augustin highlights the role of type 2 inflammation in chronic itch across distinct pruritic skin diseases and the cumulative burden of chronic itch and skin lesions in PN.
How Can FeNO Measurement Improve Severe Asthma Management?
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
